Matthew Seavey

Matthew Seavey

Company: Pelican Therapeutics (subsidiary of Heat Biologics)

Job title: Executive Director of Special Projects


As Executive Director of Research, Matthew Seavey, holds over a decade in preclinical drug development experience.  Originally trained as an immunologist and an expert in early drug development, Matt has been involved in the development of different drug modalities (biologics, small molecules, cellular therapeutics, vaccines) across multiple therapeutic areas including, GI, CNS, immuno-oncology, respiratory, inflammation and cardio-metabolics.  Matt has held former positions as Drug Discovery Team Leader at Cephalon, Global Pharmacology Project Leader at Teva Pharmaceuticals, and Oncology Program Director at United Therapeutics.  Matt is a co-inventor on several patents and has contributed to the intellectual property base of Advaxis and founding of Oncoceutics.  Most recently Matt was Director of Preclinical Pharmacology for CinRx Pharma and founding partner of BioPoint Consulting, LLC.  Matt holds a BS in Microbiology from the University of Vermont, an MSc and PhD in Immunology from the University of Rochester and an MBA from West Chester University.


A Novel TNFRSF25-Agonist for Regulatory T-cell Expansion 4:00 pm

• TNFRSF25-engagment by PTX-35 can expand regulatory T-cells in vivo and reduce disease severity in several animal models of GVHD & inflammatory disease • Favorable safety profile in monkeys; target engagement confirms Treg expansion • Plans for new indications & modalities – opportunities for partnerships • Global program status updateRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.